Recent Developments in Anti-Fungal Agents

Invasive fungal infections (IFIs) demand a tremendous levy in terms of human life and healthcare costs, despite the fact that fungal diseases are still under-diagnosed and under reported. Several factors such as patient characteristics, antifungal prophylaxis and others appear to have contributed to a change in the spectrum of invasive fungal pathogens (i.e. Candida species, Non-Candida species, Aspergillus species and Non-Aspergillus species). Therefore, it is important to recognize and minimize the major risk factors associated with infection, and expanding the antifungal drug research for new antifungal agents to treat life-threatening invasive infections. This book would highlight past and current research on fungal pathogens and antifungal therapies, and also novel targets for antifungal agents for future development in medical practice to prevent invasive fungal infections. The book will describe novel antifungal agents, its targets, and various development phases and potential benefits of combination therapy.